Free Trial
NYSEAMERICAN:TOVX

Theriva Biologics (TOVX) Stock Price, News & Analysis

Theriva Biologics logo
$2.07
+0.08 (+4.02%)
(As of 11/4/2024 ET)

About Theriva Biologics Stock (NYSEAMERICAN:TOVX)

Key Stats

Today's Range
$1.75
$2.08
50-Day Range
N/A
52-Week Range
$1.24
$17.11
Volume
2.02 million shs
Average Volume
1.02 million shs
Market Capitalization
$4.70 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Theriva Biologics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
17th Percentile Overall Score

TOVX MarketRank™: 

Theriva Biologics scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Theriva Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Theriva Biologics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Theriva Biologics has a P/B Ratio of 0.04. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    3.56% of the float of Theriva Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Theriva Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Theriva Biologics has recently decreased by 18.47%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Theriva Biologics does not currently pay a dividend.

  • Dividend Growth

    Theriva Biologics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.56% of the float of Theriva Biologics has been sold short.
  • Short Interest Ratio / Days to Cover

    Theriva Biologics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Theriva Biologics has recently decreased by 18.47%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Theriva Biologics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Theriva Biologics this week, compared to 1 article on an average week.
  • Search Interest

    Only 3 people have searched for TOVX on MarketBeat in the last 30 days. This is a decrease of -84% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Theriva Biologics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.05% of the stock of Theriva Biologics is held by insiders.

  • Percentage Held by Institutions

    Only 6.17% of the stock of Theriva Biologics is held by institutions.

  • Read more about Theriva Biologics' insider trading history.
Receive TOVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter.

TOVX Stock News Headlines

Theriva Biologics Expands Stock Plans and Share Authority
Ticking time bomb. Detonation Nov 5
Porter Stansberry’s viral Breaking Point 2024 broadcast has now been by tens of thousands of Americans who finally understand the grim reality of our next election. With November 5 just around the corner, it’s imperative for your financial future that you read Porter’s message below now and then watch Breaking Point before it’s too late.
Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) Short Interest Update
See More Headlines

TOVX Stock Analysis - Frequently Asked Questions

Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) posted its earnings results on Tuesday, August, 13th. The company reported ($5.50) EPS for the quarter.

Shares of Theriva Biologics reverse split before market open on Monday, August 26th 2024. The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Daré Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX).

Company Calendar

Last Earnings
8/13/2024
Today
11/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:TOVX
CIK
N/A
Employees
22
Year Founded
N/A

Profitability

Net Income
$-18,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$54.22 per share

Miscellaneous

Free Float
2,204,000
Market Cap
$4.29 million
Optionable
Not Optionable
Beta
1.34
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NYSEAMERICAN:TOVX) was last updated on 11/4/2024 by MarketBeat.com Staff
From Our Partners